Core Insights - Alnylam Pharmaceuticals has faced challenges in the last three months due to slowing sales at a key rival, raising concerns about the overall health of the transthyretin amyloidosis (TTR) market [1] Company Summary - Alnylam Pharmaceuticals is experiencing difficulties linked to competitive pressures in the TTR space, which may impact its market position and sales performance [1]